Caribou Biosciences to Participate in Upcoming Investor Conferences

GlobeNewswire

2025/11/04

BERKELEY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will participate in the following investor conferences:

2025 Truist Securities BioPharma Symposium, New York
November 6, 2025

8th Annual Evercore Healthcare Conference, Coral Gables, FL
December 2, 2025 with fireside chat at 8:45-9:05 AM ET
Webcast

For more information and links to webcasts, please visit the Events page on Caribou’s website. Webcasts will be available on the Caribou website for at least 30 days after the event.

About Caribou Biosciences, Inc.
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. Caribou is focused on vispacabtagene regedleucel (vispa-cel) and CB-011 as off-the-shelf CAR-T cell therapies that have the potential to provide broad access and rapid treatment for patients with hematologic malignancies.

Caribou Biosciences, Inc. contact:
Peggy Vorwald, PhD
media@cariboubio.com
investor.relations@cariboubio.com

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎国际,美股交易,港股交易,交易美股,股票信息,股价,美股行情,美股打新,港股打新,IPO打新,购买美股,全球投资","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2580229974"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580229974\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580229974?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 06:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580229974","market":"us","top_or_hot":-1,"title":"Caribou Biosciences to Participate in Upcoming Investor Conferences","media":"GlobeNewswire","content":"<html><body><p>BERKELEY, Calif., Nov.  03, 2025  (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/CRBU\">Caribou Biosciences</a>, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will participate in the following investor conferences:</p> <ul type=\"disc\"><li><strong>2025 Truist Securities BioPharma Symposium</strong>, New York<br/>November 6, 2025</li></ul> <ul type=\"disc\"><li><strong>8th Annual <a href=\"https://laohu8.com/S/EVR\">Evercore</a> Healthcare Conference,</strong> Coral Gables, FL<br/>December 2, 2025 with fireside chat at 8:45-9:05 AM ET<br/>Webcast<br/><br/></li></ul> <p>For more information and links to webcasts, please visit the Events page on Caribou’s website. Webcasts will be available on the Caribou website for at least 30 days after the event.</p> <p><strong>About Caribou Biosciences, Inc.<br/></strong>Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. Caribou is focused on vispacabtagene regedleucel (vispa-cel) and CB-011 as off-the-shelf CAR-T cell therapies that have the potential to provide broad access and rapid treatment for patients with hematologic malignancies.</p> <p><strong>Caribou Biosciences, Inc. contact:<br/></strong>Peggy Vorwald, PhD<br/>media@cariboubio.com<br/>investor.relations@cariboubio.com</p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/NzAzZmYzYzEtNWI0Ni00NDFlLThlYmQtZTBjMTU4ODQ2MGVmLTEyMjEwNzYtMjAyNS0xMS0wMy1lbg==/tiny/Caribou-Biosciences-Inc-.png\"/></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Caribou Biosciences to Participate in Upcoming Investor Conferences</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCaribou Biosciences to Participate in Upcoming Investor Conferences\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1016364462\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">GlobeNewswire </p>\n<p class=\"h-time\">2025-11-04 06:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>BERKELEY, Calif., Nov.  03, 2025  (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/CRBU\">Caribou Biosciences</a>, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will participate in the following investor conferences:</p> <ul type=\"disc\"><li><strong>2025 Truist Securities BioPharma Symposium</strong>, New York<br/>November 6, 2025</li></ul> <ul type=\"disc\"><li><strong>8th Annual <a href=\"https://laohu8.com/S/EVR\">Evercore</a> Healthcare Conference,</strong> Coral Gables, FL<br/>December 2, 2025 with fireside chat at 8:45-9:05 AM ET<br/>Webcast<br/><br/></li></ul> <p>For more information and links to webcasts, please visit the Events page on Caribou’s website. Webcasts will be available on the Caribou website for at least 30 days after the event.</p> <p><strong>About Caribou Biosciences, Inc.<br/></strong>Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. Caribou is focused on vispacabtagene regedleucel (vispa-cel) and CB-011 as off-the-shelf CAR-T cell therapies that have the potential to provide broad access and rapid treatment for patients with hematologic malignancies.</p> <p><strong>Caribou Biosciences, Inc. contact:<br/></strong>Peggy Vorwald, PhD<br/>media@cariboubio.com<br/>investor.relations@cariboubio.com</p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/NzAzZmYzYzEtNWI0Ni00NDFlLThlYmQtZTBjMTU4ODQ2MGVmLTEyMjEwNzYtMjAyNS0xMS0wMy1lbg==/tiny/Caribou-Biosciences-Inc-.png\"/></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRBU","symbol_name":"Caribou Biosciences","start_time":0,"source_url":"https://www.globenewswire.com/news-release/2025/11/03/3179891/0/en/Caribou-Biosciences-to-Participate-in-Upcoming-Investor-Conferences.html","article_id":"2580229974","we_media_id":"1016364462","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580229974","pubTimestamp":1762208100,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"GlobeNewswire","introduction":"Share your news with media, investors, and consumers with targeted distribution options from one of the world’s largest and most trusted newswires.","home_visible":1,"id":"1016364462","head_image":"https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a"},"summary":"BERKELEY, Calif., Nov.  03, 2025  (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management wil","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CRBU":"Caribou Biosciences","BK4556":"基因编辑","BK4585":"ETF&股票定投概念","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4139":"生物科技","BK4611":"AI医疗","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","CRSP":"CRISPR Therapeutics AG","BK4588":"碎股","BK4539":"次新股"},"translate_title":"Caribou Biosciences将参加即将举行的投资者会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRSP":0.65,"CRBU":1.5},"content_text":"BERKELEY, Calif., Nov.  03, 2025  (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will participate in the following investor conferences: 2025 Truist Securities BioPharma Symposium, New YorkNovember 6, 2025 8th Annual Evercore Healthcare Conference, Coral Gables, FLDecember 2, 2025 with fireside chat at 8:45-9:05 AM ETWebcast For more information and links to webcasts, please visit the Events page on Caribou’s website. Webcasts will be available on the Caribou website for at least 30 days after the event. About Caribou Biosciences, Inc.Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. Caribou is focused on vispacabtagene regedleucel (vispa-cel) and CB-011 as off-the-shelf CAR-T cell therapies that have the potential to provide broad access and rapid treatment for patients with hematologic malignancies. Caribou Biosciences, Inc. contact:Peggy Vorwald, PhDmedia@cariboubio.cominvestor.relations@cariboubio.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}